Search research articles
Contact Us
Filters
Showing results (81-90 of 150) with videos related to
Page
of 15
Sort By:
Cancer Biology & Therapy
|
April 14, 2018
CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients
Nicholas C Nicolaides, Charles Schweizer, Elizabeth B Somers, et al.
Cancer
|
July 4, 2014
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125
Raffit Hassan, Elad Sharon, Anish Thomas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 10, 2021
Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations
Zishuo I Hu, Markku Miettinen, Martha Quezado, et al.
Clinical Chemistry and Laboratory Medicine
|
December 14, 2011
Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers
Elad Sharon, Jingli Zhang, Kevin Hollevoet, et al.
Journal of Patient-Reported Outcomes
|
June 19, 2019
Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)
Tito R Mendoza, Loretta A Williams, Karen N Keating, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2006
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer
Raffit Hassan, Alan T Remaley, Maureen L Sampson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 18, 2006
Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts
Raffit Hassan, Juanita Williams-Gould, Seth M Steinberg, et al.
The Journal of Applied Laboratory Medicine
|
October 30, 2018
Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer
Yunkai Yu, Bríd M Ryan, Anish Thomas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 22, 2016
Malignant Mesothelioma Effusions Are Infiltrated by CD3<sup>+</sup> T Cells Highly Expressing PD-L1 and the PD-L1<sup>+</sup> Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab
Swati Khanna, Anish Thomas, Daniel Abate-Daga, et al.
Molecular Cancer Therapeutics
|
May 2, 2022
Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
Sakshi Tomar, Jingli Zhang, Manakamana Khanal, et al.
Page
of 15
Search research articles
Search
Showing results (81-90 of 150) with videos related to
Sort By:
Page
of 15
Cancer Biology & Therapy
|
April 14, 2018
CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients
Nicholas C Nicolaides, Charles Schweizer, Elizabeth B Somers, et al.
Cancer
|
July 4, 2014
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125
Raffit Hassan, Elad Sharon, Anish Thomas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 10, 2021
Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations
Zishuo I Hu, Markku Miettinen, Martha Quezado, et al.
Clinical Chemistry and Laboratory Medicine
|
December 14, 2011
Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers
Elad Sharon, Jingli Zhang, Kevin Hollevoet, et al.
Journal of Patient-Reported Outcomes
|
June 19, 2019
Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)
Tito R Mendoza, Loretta A Williams, Karen N Keating, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2006
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer
Raffit Hassan, Alan T Remaley, Maureen L Sampson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 18, 2006
Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts
Raffit Hassan, Juanita Williams-Gould, Seth M Steinberg, et al.
The Journal of Applied Laboratory Medicine
|
October 30, 2018
Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer
Yunkai Yu, Bríd M Ryan, Anish Thomas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 22, 2016
Malignant Mesothelioma Effusions Are Infiltrated by CD3<sup>+</sup> T Cells Highly Expressing PD-L1 and the PD-L1<sup>+</sup> Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab
Swati Khanna, Anish Thomas, Daniel Abate-Daga, et al.
Molecular Cancer Therapeutics
|
May 2, 2022
Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
Sakshi Tomar, Jingli Zhang, Manakamana Khanal, et al.
Page
of 15